Update on FDA ’s ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity
.
Preliminary evaluation does not suggest a causal link. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 11, 2024 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Strict Glycemic Control for Renal Benefit May Come With Risk Strict Glycemic Control for Renal Benefit May Come With Risk
A new study explores if the kidney failure risk equation can identify patients with type 2 diabetes who would show renal improvement with intensive glycemic management.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - January 11, 2024 Category: Endocrinology Tags: Nephrology Source Type: news
Life With Insulin Injections
Treating your type 2 diabetes with insulin? Learn the ins and outs of giving yourself daily injections. (Source: WebMD Health)
Source: WebMD Health - January 10, 2024 Category: Consumer Health News Source Type: news
American Heart Association Announces CKM Syndrome to Describe ‘Strong Connection’ between Multiple Diseases
Newly-defined Cardiovascular-Kidney-Metabolic Syndrome (CKM) means physicians with be in close collaboration with clinical laboratories to make accurate diagnoses Based on newly-identified “strong connections” between cardiovascular disease (CVD, or heart disease), kidney disease, Type 2 diabetes, and obesity, the American Heart Association (AHA) is calling for a “redefining” of the risk, prevention, and management of CVD, […]
The post American Heart Association Announces CKM Syndrome to Describe ‘Strong Connection’ between Multiple Diseases appeared first on Dark Daily. (Source: Dark Daily)
Source: Dark Daily - January 10, 2024 Category: Laboratory Medicine Authors: Jillia Schlingman Tags: Laboratory News Laboratory Pathology Laboratory Resources Laboratory Testing Precision Medicine AHA American Heart Association anatomic pathology cardiovascular disease Cardiovascular-Kidney-Metabolic Syndrome CDC Centers of Disease Source Type: news
Risk for Suicidal Ideation Not Increased With Semaglutide
TUESDAY, Jan. 9, 2024 -- For individuals with overweight or obesity and type 2 diabetes, semaglutide is not associated with an increased risk for suicidal ideation compared with non-glucagon-like peptide 1 receptor (GLP1R) agonist antiobesity... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 9, 2024 Category: Pharmaceuticals Source Type: news
No Increased Risk of Suicidal Ideation With GLP-1 Drugs
(MedPage Today) -- Despite recent concerns to the contrary, semaglutide (Wegovy, Ozempic) carried a lower risk of suicidal ideation in patients with obesity or type 2 diabetes, according to retrospective analyses of the two patient populations... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 8, 2024 Category: American Health Source Type: news
Semaglutide associated with lower risk of suicidal ideations compared to other treatments prescribed for obesity or type 2 diabetes
NIH-funded analysis finds patients treated with semaglutide had 49% to 73% lower risk of suicidal ideation than those given other medications. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - January 5, 2024 Category: American Health Source Type: news
Semaglutide associated with lower risk of suicidal ideations compared to other treatments prescribed for obesity or type 2 diabetes
Analysis finds patients treated with semaglutide had 49% to 73% lower risk of suicidal ideation (Source: NIDA News)
Source: NIDA News - January 5, 2024 Category: Addiction Tags: Mental Health, Treatment Research, News Release Source Type: news
In Acute Kidney Disease, SGLT2 inhibitors Were All-Around Protective
(MedPage Today) -- SGLT2 inhibitors significantly lowered the risk of death, major adverse kidney events (MAKE), and major adverse cardiovascular events (MACE) in people with type 2 diabetes and acute kidney disease, according to a cohort study... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 4, 2024 Category: Cardiology Source Type: news
Yale expert addresses diabetes crisis at Senate committee hearing
Yale ’s Kasia Lipska provided testimony on the reasons behind the increase in type 2 diabetes in the U.S. and ways to expand treatment availability. (Source: Yale Science and Health News)
Source: Yale Science and Health News - January 3, 2024 Category: Universities & Medical Training Source Type: news
'I'm a doctor - the way you walk could slash your risk of type 2 diabetes by 39%'
Walking at a certain speed could see your chances of type 2 diabetes fall significantly. (Source: Daily Express - Health)
Source: Daily Express - Health - January 2, 2024 Category: Consumer Health News Source Type: news
What to Know About Heart Failure When You Have Diabetes
In June of 2022, a report from the American Diabetes Association highlighted heart failure as “an underappreciated complication of diabetes.” According to that report, up to 22% of people with diabetes will develop heart failure, and the incidence of heart failure within the diabetes community is increasing.
“Heart failure is the most prevalent cardiovascular complication in people with diabetes,” says Dr. Rodica Pop-Busui, a professor of diabetes at the University of Michigan and president of medicine and science at the American Diabetes Association. “In the U.S. alone there are 37 million...
Source: TIME: Health - December 29, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized healthscienceclimate Source Type: news
Sustained Weight Loss Linked to Lower Renal Risk in Diabetes Sustained Weight Loss Linked to Lower Renal Risk in Diabetes
Researchers report an independent inverse link between time spent within a target body weight range and composite kidney outcomes in individuals with overweight/obesity and type 2 diabetes.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 29, 2023 Category: Endocrinology Tags: Nephrology Source Type: news
Dapagliflozin Cuts Cardiovascular Events in Patients With Heart Failure, T2D
WEDNESDAY, Dec. 27, 2023 -- For patients with heart failure and type 2 diabetes (T2D), dapagliflozin does not reduce urinary albumin-to-creatinine ratio (UACR) but does reduce some cardiovascular events, according to a study published online Nov. 27... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2023 Category: Pharmaceuticals Source Type: news
